12 Stocks That Will Double in 2025

Page 6 of 11

6. IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Analyst Upside as of January 28, 2025: 144%

Number of Hedge Fund Holders: 38

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) ranks sixth on our list of stocks expected to double in 2025. IDYA is a clinical-stage precision medicine oncology company committed to the development of targeted therapeutics for patient populations using molecular diagnostics. In a solid update before the end of 2024, the company announced its exclusive license with Jiangsu Hengrui Pharmaceuticals Co., Ltd. to work towards the development and commercialization of SHR-4849, a phase-1 antibody drug.

On January 15, Justin Zelin, an analyst at BTIG, maintained a buy rating on IDEAYA Biosciences, Inc. (NASDAQ:IDYA) and a price target of $62. Zelin’s bullish stance on the stock is based on the company’s promising pipeline and strategic updates for 2025. The analyst believes these updates are crucial to the potential value IDYA can provide to the industry. Zelin is also optimistic about the company’s expanding datasets, possibly resulting in improved patient outcomes.

Overall, the company’s growing pipeline positions IDEAYA Biosciences, Inc. (NASDAQ:IDYA) as an emerging leader in the biotechnology industry, which is supported by its expansion strategies. Analysts are also bullish on the stock with a median price target of $58.5, an upside of 144% from current levels.

Page 6 of 11